Literature DB >> 20305560

What can we learn from epigenetics in the year 2009?

Astrid Jüngel1, Caroline Ospelt, Steffen Gay.   

Abstract

PURPOSE OF REVIEW: Rheumatoid arthritis (RA) is a systemic, autoimmune disease resulting in the destruction of affected joints. Even though current therapies with biologics such as tumor necrosis factor-alpha blockers yield significant improvement for the patients, the disease is not curable yet. Therefore, we need novel strategies for better therapies. RECENT
FINDINGS: The growing knowledge of epigenetics might give us new insights into the pathogenesis of autoimmune diseases. In the last year, several new findings about epigenetic modifications of gene expression were reported in different arthritides. These modifications describe changes in the expression of DNA that result from methylation, posttranslational modifications of the histone proteins, including acetylation/deacetylation, sumoylation, methylation and microRNAs. Most interestingly, these modifications seem to act in concert and are associated with the circadian metabolic rhythm of cells.
SUMMARY: This review summarizes reports from the last year about epigenetic modifications of gene expression via acetylation/deacetylation, including sirtuins, sumoylation, methylation, microRNAs in all in rheumatoid arthritis and other arthritides, providing potential strategies for better therapies and encourages the development of specific epigenetic drugs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20305560     DOI: 10.1097/BOR.0b013e3283389641

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  14 in total

1.  Citrullinated calreticulin potentiates rheumatoid arthritis shared epitope signaling.

Authors:  Song Ling; Erika N Cline; Timothy S Haug; David A Fox; Joseph Holoshitz
Journal:  Arthritis Rheum       Date:  2013-03

Review 2.  Fetal stress and programming of hypoxic/ischemic-sensitive phenotype in the neonatal brain: mechanisms and possible interventions.

Authors:  Yong Li; Pablo Gonzalez; Lubo Zhang
Journal:  Prog Neurobiol       Date:  2012-05-22       Impact factor: 11.685

Review 3.  Cutting edge: the etiology of autoimmune thyroid diseases.

Authors:  Deirdre Cocks Eschler; Alia Hasham; Yaron Tomer
Journal:  Clin Rev Allergy Immunol       Date:  2011-10       Impact factor: 8.667

Review 4.  Genetic and epigenetic mechanisms in thyroid autoimmunity.

Authors:  Alia Hasham; Yaron Tomer
Journal:  Immunol Res       Date:  2012-12       Impact factor: 2.829

Review 5.  HDAC inhibition in rheumatoid arthritis and juvenile idiopathic arthritis.

Authors:  Jelena Vojinovic; Nemanja Damjanov
Journal:  Mol Med       Date:  2011-02-04       Impact factor: 6.354

Review 6.  Mechanisms of autoimmune thyroid diseases: from genetics to epigenetics.

Authors:  Yaron Tomer
Journal:  Annu Rev Pathol       Date:  2014       Impact factor: 23.472

Review 7.  The role of stromal cells in the persistence of chronic inflammation.

Authors:  A J Naylor; A Filer; C D Buckley
Journal:  Clin Exp Immunol       Date:  2013-01       Impact factor: 4.330

Review 8.  Cardiovascular risk in systemic autoimmune diseases: epigenetic mechanisms of immune regulatory functions.

Authors:  Chary López-Pedrera; Carlos Pérez-Sánchez; Manuel Ramos-Casals; Monica Santos-Gonzalez; Antonio Rodriguez-Ariza; Ma José Cuadrado
Journal:  Clin Dev Immunol       Date:  2011-09-14

9.  Direct chromatin PCR (DC-PCR): hypotonic conditions allow differentiation of chromatin states during thermal cycling.

Authors:  Sergei Vatolin; Shahper N Khan; Frederic J Reu
Journal:  PLoS One       Date:  2012-09-12       Impact factor: 3.240

10.  MicroRNA-125b: association with disease activity and the treatment response of patients with early rheumatoid arthritis.

Authors:  Veronika Hruskova; Romana Jandova; Lucia Vernerova; Herman Mann; Ondrej Pecha; Klara Prajzlerova; Karel Pavelka; Jiri Vencovsky; Maria Filkova; Ladislav Senolt
Journal:  Arthritis Res Ther       Date:  2016-06-02       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.